1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Aarey Drugs & Pharmaceuticals Limited

Aarey Drugs & Pharmaceuticals Limited

AAREYDRUGS.NS
Aarey Drugs & Pharmaceuticals LimitedIN flagNational Stock Exchange of India
82.83
INR
-1.69
- -
2.35BMarket Cap
Aarey Drugs & Pharmaceuticals Limited
AAREYDRUGS.NS
(National Stock Exchange of India)

Recent

price

82.83

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
112.79
93.12
102.47
118.78
126.94
146.32
218.95
149.09
151.68
128.33
148.77
204.2
162.64
155.47
167.25
165.45
166.2
Revenue per Share
1.32
0.2
0.39
0.63
0.65
0.77
3.03
2.64
2.8
2.48
2.79
2.72
1.49
1.84
1.42
1.39
1.59
Basic EPS, GAAP
-19.33
-6.41
1.91
-0.8
0.49
1.83
-2.38
-8.97
-0.24
0.83
1.11
-0.71
-0.92
-1.46
1.8
-0.8
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
0.1
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
16.33
13.63
13.41
14.04
14.57
14.66
17.36
18.34
21.03
23.51
26.3
29.09
29.08
31.94
30.2
9.97
10.01
Book Value per Share
36.51
23.42
19.91
20.53
21.06
21.16
27.2
34.32
37.01
39.49
42.28
47.2
46.25
52.24
48.87
52.7
52.94
Tangible Book Value per Share
6
14
17
17
17
17
18
23
23
23
23
24
25
25
28
29
28
Basic Weighted Avg Shares
677
1,305
1,723
1,997
2,134
2,460
3,960
3,486
3,547
3,001
3,479
4,916
4,128
3,951
4,739
4,723
4,723
Sales/Revenue/Turnover
1.66
0.86
0.93
0.44
0.23
0.26
2.28
2.09
1.95
0.78
1.07
1.93
0.49
0.71
0.2
0.91
0.92
Operating Margin (%)
5
6
6
6
11
6
6
7
10
9
9
20
16
17
19
29
29
Depreciation Expense
8
3
7
11
11
13
55
62
65
58
65
66
38
47
40
40
45
Net Income, GAAP
20.59
30.95
27.07
21.63
22.81
28.88
31.39
24.59
27.2
20
21.53
34.69
37.25
12.34
34.05
26.72
16.48
Effective Tax Rate (%)
1.17
0.22
0.38
0.53
0.51
0.52
1.38
1.77
1.84
1.93
1.87
1.33
0.91
1.19
0.85
0.84
0.96
Profit Margin (%)
165
279
259
293
290
285
382
691
754
811
876
921
1,025
1,160
1,164
1,179
1,179
Working Capital
- -
- -
2
- -
- -
1
1
1
- -
- -
- -
33
44
32
20
10
10
LT Debt
219
328
335
345
354
356
492
802
866
923
989
1,136
1,174
1,328
1,385
1,504
1,504
Total Equity
4.57
2.48
3.08
1.75
0.89
0.93
10.98
7.38
5.19
1.7
2.5
4.92
0.86
1.52
0.37
1.69
1.93
Return on Invested Capital (%)
5.91
1.55
2.58
6.21
6.29
6.38
20.72
17.13
14.54
10.34
10.94
9.53
5.53
7.55
6.1
7.68
8.75
Return on Capital (%)
8.41
1.97
3.16
4.55
4.53
5.25
19.53
16.63
14.21
11.12
11.19
9.97
5.24
6.04
4.83
6.96
7.93
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
495
- -
490
LT Borrowings
13
- -
10
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
28
- -
28
Market Capitalization
2,340
1,912
1,442

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
2,564
- -
2,629
Cash, Cash Equivalents & STI
82
- -
34
Accounts Receivable, Net
1,223
- -
1,297
Inventories
391
- -
415
Total Current Liabilities
1,428
- -
1,451
Payables & Accruals
- -
- -
- -
ST Debt
495
- -
490
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.73%
8.85%
8.62%
Free Cash Flow
-81.41%
-90.17%
-144.58%
Net Income, GAAP
31.12%
-6.63%
-1.4%
Sales/Revenue/Turnover
9.19%
8.12%
-0.35%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
510
578
765
2,098
3,951
2025
1,269
1,051
1,338
1,081
4,739
2026
1,022
842
964
1,895
4,723

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.29
0.31
0.4
- -
1.84
2025
0.44
0.57
0.25
0.17
1.42
2026
0.48
0.36
0.2
0.55
1.39

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Torii Pharmaceutical Co., Ltd. (TRXPF)
Lionco Pharmaceutical Group Co.,Ltd. (603669.SS)
Radient Technologies Inc. (RDDTF)
Pharmanutra S.p.A. (PHN.MI)
Lasa Supergenerics Limited (LASA.NS)
JW Holdings Corporation (096760.KS)
Business
Aarey Drugs & Pharmaceuticals Limited manufactures active pharmaceutical ingredients, pharmaceutical intermediates, and specialty chemicals; trades industrial solvents and chemicals; and provides contract manufacturing, custom synthesis, and research and development services for the pharmaceutical and chemical industries. The company produces specific APIs including Metformin, Mefenamic Acid, and Doxaphylline; intermediates such as N-Methyl Urea and Dimethyl Urea; specialty chemicals like aromatic chemicals, chemical acids, and chloralkaline products; and industrial solvents encompassing alcohols, ketones, and glycols. Its products serve pharmaceutical formulation manufacturers, merchant exporters, and various industrial sectors globally, with manufacturing facilities in Tarapur and operations primarily in India. Incorporated in 1990 and headquartered at 107, Sahakar Bhavan, 340/348 Narshi Natha Street, Masjid, Mumbai, India, the company operates as a public limited entity listed on the Bombay Stock Exchange under the ticker AAREYDRUGS.NS. In recent developments, Aarey Drugs & Pharmaceuticals approves a preferential issue of shares or warrants at its board meeting on December 4, 2024, to raise funds; allots convertible warrants pursuant to a preferential issue; announces plans to issue 5 million warrants; and receives funding as reported in early 2025. The company also appoints a new Company Secretary and Compliance Officer in March 2025, changes its Registrar and Transfer Agent, and reappoints a director amid ongoing strategic funding efforts. These initiatives support business expansion and capital strengthening within the last year.